A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 15 Jun 2023
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms PURSUIT - Maintenance; Pursuit-M
- Sponsors Janssen Research & Development
- 01 Jun 2023 Results of post-hoc pooled analysis of two studies ( PURSUIT-SC & PURSUIT - Maintenance) assessing effect of race on response to golimumab, published in the Inflammatory Bowel Diseases.
- 13 Oct 2020 Results assessing quality of life outcomes presented at the 28th United European Gastroenterology Week
- 22 Jan 2020 Results assessing the population pharmacokinetic (PK) properties of golimumab and exposure-response for efficacy and safety, using data from combined Phase II/III UC studies (NCT00488774, NCT00487539, and NCT00488631) published in the Clinical Therapeutics